146 related articles for article (PubMed ID: 28059167)
1. Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.
Gracio F; Burford B; Gazinska P; Mera A; Mohd Noor A; Marra P; Gillett C; Grigoriadis A; Pinder S; Tutt A; de Rinaldis E
Sci Rep; 2017 Jan; 7():40177. PubMed ID: 28059167
[TBL] [Abstract][Full Text] [Related]
2. A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.
Villemin JP; Lorenzi C; Cabrillac MS; Oldfield A; Ritchie W; Luco RF
BMC Biol; 2021 Apr; 19(1):70. PubMed ID: 33845831
[TBL] [Abstract][Full Text] [Related]
3. Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer.
Aversa R; Sorrentino A; Esposito R; Ambrosio MR; Amato A; Zambelli A; Ciccodicola A; D'Apice L; Costa V
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784191
[TBL] [Abstract][Full Text] [Related]
4. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of alternative transcripts in human breast cancer.
Wen J; Toomer KH; Chen Z; Cai X
Breast Cancer Res Treat; 2015 Jun; 151(2):295-307. PubMed ID: 25913416
[TBL] [Abstract][Full Text] [Related]
6. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.
Dowhan DH; Harrison MJ; Eriksson NA; Bailey P; Pearen MA; Fuller PJ; Funder JW; Simpson ER; Leedman PJ; Tilley WD; Brown MA; Clarke CL; Muscat GE
Endocr Relat Cancer; 2012 Aug; 19(4):509-26. PubMed ID: 22673335
[TBL] [Abstract][Full Text] [Related]
7. Decreased Usage of Specific Scrib Exons Defines a More Malignant Phenotype of Breast Cancer With Worsened Survival.
Metodieva G; Adoki S; Lausen B; Metodiev MV
EBioMedicine; 2016 Jun; 8():150-158. PubMed ID: 27428426
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic long noncoding RNA landscape in breast cancer.
Xu S; Kong D; Chen Q; Ping Y; Pang D
Mol Cancer; 2017 Jul; 16(1):129. PubMed ID: 28738804
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
10. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ
Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621
[TBL] [Abstract][Full Text] [Related]
11. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene.
Watermann DO; Tang Y; Zur Hausen A; Jäger M; Stamm S; Stickeler E
Cancer Res; 2006 May; 66(9):4774-80. PubMed ID: 16651431
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.
Coyle KM; Murphy JP; Vidovic D; Vaghar-Kashani A; Dean CA; Sultan M; Clements D; Wallace M; Thomas ML; Hundert A; Giacomantonio CA; Helyer L; Gujar SA; Lee PW; Weaver IC; Marcato P
Oncotarget; 2016 Jul; 7(28):44096-44112. PubMed ID: 27286452
[TBL] [Abstract][Full Text] [Related]
13. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
[TBL] [Abstract][Full Text] [Related]
14. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
15. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
16. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.
Garczyk S; Klotz N; Szczepanski S; Denecke B; Antonopoulos W; von Stillfried S; Knüchel R; Rose M; Dahl E
Oncotarget; 2017 May; 8(22):36246-36265. PubMed ID: 28423716
[TBL] [Abstract][Full Text] [Related]
18. Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.
Teschendorff AE; Li L; Yang Z
Genome Biol; 2015 Apr; 16(1):61. PubMed ID: 25886003
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.
Gardina PJ; Clark TA; Shimada B; Staples MK; Yang Q; Veitch J; Schweitzer A; Awad T; Sugnet C; Dee S; Davies C; Williams A; Turpaz Y
BMC Genomics; 2006 Dec; 7():325. PubMed ID: 17192196
[TBL] [Abstract][Full Text] [Related]
20. From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
Tian N; Li J; Shi J; Sui G
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
